UCB making strides to becoming a key player in the myasthaenia gravis market
UCB is planning to file regulatory submissions for both its pipeline myasthaenia gravis drugs later this year.
By
UCB is planning to file regulatory submissions for both its pipeline myasthaenia gravis drugs later this year.
ByAfter Biogen all but waved the white flag on its once-promising Aduhelm, Clinical Trials Arena explores how Alzheimer’s disease drug…
ByMitsubishi Tanabe is developing an oral formulation of edaravone, MT-1186, in an effort to increase uptake and drive down costs.
ByAbbVie’s Ubrelvy has been found to cause high satisfaction in achieving pain relief and the ability to think clearly in…
ByATH434 received Orphan designation from the US Food and Drug Administration and the European Commission for MSA treatment.
Botox treatment has shown a significant reduction in the frequency, severity and duration of headaches among migraine patients.
ByMajor depressive disorder (MDD), also known as clinical depression or major depression, is widely recognised as a mood disorder that…
ByTopline results from the trial are anticipated during the fourth quarter of this year.